Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
about
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgReduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography.Enzyme replacement therapy for Anderson-Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseaseLong-term safety and efficacy of enzyme replacement therapy for Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseaseIs 2D speckle tracking echocardiography useful for detecting and monitoring myocardial dysfunction in adult m.3243A>G carriers? - a retrospective pilot studyReproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonanceTissue Doppler and strain imaging: anything left in the echo-lab?Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes.Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) dataAnalysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.Arrhythmias in Fabry cardiomyopathy.Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activityEnzyme replacement therapy for Fabry disease: some answers but more questionsLong-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsNewborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry diseaseConsequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.The natural history of left ventricular systolic function in Anderson-Fabry disease.Cellular and tissue distribution of intravenously administered agalsidase alfa.Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase AThe heart in Anderson-Fabry disease and other lysosomal storage disorders.The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis?Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutationsCardiac magnetic resonance in myocardial diseaseInflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry diseaseFabry disease: guidelines for the evaluation and management of multi-organ system involvement.Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.Fabry cardiomyopathy.Novel therapeutic targets for the treatment of Fabry disease.Unexplained left ventricular hypertrophy: consider a diagnosis of Fabry's disease.Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.Fibrosis: a key feature of Fabry disease with potential therapeutic implications
P2860
Q21004071-CD395368-37BD-4041-9823-C4EAE11A536CQ21245672-9A936728-5035-4B4F-A1D8-0512BA17502DQ24200877-6236003E-EF10-4810-AE95-3F7E5A3FF75DQ24235483-4CBFA3A8-17BE-4CD8-A1F3-810AE09DF059Q24533551-996DC2C5-0CEE-402A-AF8C-BD621F8C3721Q26471010-B5367804-91E6-496B-911D-889804AE1995Q30362604-7123FCE7-C243-463A-BBCF-043499C8BA87Q30423465-1AF3421F-41AA-401D-8948-C9966AE5ECCEQ30492698-BE2824A2-B808-4862-932A-D0E7F250427AQ30499724-B9045796-B321-46AD-A93B-01540FAC8D59Q30578294-E2132BDD-435D-42D4-A022-0234C9AB80A5Q30632134-E571A882-1B56-4A11-8C49-CF0F40E8007EQ33161649-4ADFD5D3-612C-442E-A532-835D35C5BD82Q34030488-101F59C3-5438-438C-95AE-48CD5EC659E4Q34703815-465C1D0C-3F1F-4E62-84EC-F8720F333D6EQ34805283-A53AC935-7B1B-47EC-94E8-6E1859C17133Q34993215-53CDCECE-F149-42E7-A734-E556F9B5F811Q35104405-B56B3C73-ED5E-449D-9838-51BDA68C2410Q35560027-F40D7EE0-A1BD-4A9B-AB52-E97960AEF362Q35584050-D8AC9FC6-70E5-465A-B0D7-88C0CDA2FFB4Q35728693-70F54E57-C9B0-4EC7-B062-57075C55B293Q35771337-60FF444A-49CC-4C1A-A9C4-671B217526FAQ35773435-2610B572-A63F-4B28-A76D-FCABF15DF9CBQ35775374-CAC3ADED-8A93-42B5-AEBD-EE055BBAEFF0Q35842694-68F5B214-DFA0-4EB1-B482-6185B33F3760Q36061578-C5900CC6-F610-4620-A665-6AE7280895DEQ36097772-10BE4E3F-E9D7-41BA-8204-96635ADD262EQ36130925-E3424881-FC3C-4FD7-BC80-1AA9EE0B7042Q36498834-ACBF50D3-EC7A-4C23-A0AF-86B4B558DAADQ36560495-FF7F1043-C69B-4D3A-99C4-CD22011DBAA8Q36590934-3B9B7417-2A8A-4426-A0CA-89A712B3C42FQ36596408-7DA77A8F-AF4B-4A06-BB7F-3613310FFF40Q36624746-B18E8565-DC6F-4988-A502-4C87FAD05294Q36691040-770FFE70-3B48-4A86-8AEC-36428170E1C2Q36725528-D514BB04-EAAA-4157-8C76-EC3F0A4F7148Q36822452-A6553D44-72BD-447A-BA60-28E7AACA52D6Q36917375-6A0CDB38-8CDB-4B49-9D6A-CABE047F5EE0Q37029946-618474D5-5ACB-4A7F-9B57-2A176CD43B23Q37076050-7415D6BB-9E16-465C-9B8A-112C9A2036F6Q37113004-664D2C5B-1ED0-4354-AC1C-16D238795816
P2860
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Improvement of cardiac functio ...... ive strain rate imaging study.
@en
Improvement of cardiac functio ...... ive strain rate imaging study.
@nl
type
label
Improvement of cardiac functio ...... ive strain rate imaging study.
@en
Improvement of cardiac functio ...... ive strain rate imaging study.
@nl
prefLabel
Improvement of cardiac functio ...... ive strain rate imaging study.
@en
Improvement of cardiac functio ...... ive strain rate imaging study.
@nl
P2093
P1433
P1476
Improvement of cardiac functio ...... ive strain rate imaging study.
@en
P2093
Anita Knoll
Christoph Wanner
Frank Breunig
Frank Weidemann
Georg Ertl
Joern Sandstede
Jörg M Strotmann
Meinrad Beer
Oliver Turschner
Wolfram Voelker
P304
P356
10.1161/01.CIR.0000091253.71282.04
P407
P577
2003-09-02T00:00:00Z